A Randomized Study of Three Medication Regimens for Acute Low Back Pain
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Low back pain causes 2.4% of visits to US emergency departments (ED) resulting in 2.7 million visits annually. In a general low back pain (LBP) population, prognosis is poor. About 50% of patients who visited general practitioners with new onset musculoskeletal LBP report persistent pain and functional disability three months after the index visit. Outcomes are similarly poor for the population of patients forced to use an ED for management of their LBP. In an observational study of patients with non-traumatic LBP recently completed at the PI's institution, patients were contacted one week after ED discharge: 70% reported persistent back-pain related functional impairment, 59% reported moderate or severe LBP, and 69% reported analgesic use within the previous 24 hours. Three months after the ED visit, 48% reported functional impairment, 42% reported moderate or severe pain, and 46% reported analgesic use within the previous 24 hours.
A variety of evidence-based medications are available to treat LBP. Non-steroidal anti-inflammatory drugs (NSAID) are more efficacious than placebo with regard to pain relief, global improvement, and requirement of analgesic medication. Skeletal muscle-relaxants too are effective for short-term pain relief and global efficacy. Opioids are commonly used for moderate or severe acute LBP,(9) though high-quality evidence supporting this practice is lacking.
Treatment of LBP with multiple concurrent medications is common in the ED setting. Emergency physicians often prescribe NSAIDs, skeletal muscle relaxants, and opioids in combination. Several clinical trials have compared combination therapy with NSAIDS+ skeletal muscle relaxants to monotherapy with just one of these agents. These trials have reported heterogeneous results. The combination of opioids + NSAIDS has not been evaluated experimentally in patients with acute LBP.
Given the poor pain and functional outcomes that persist beyond an ED visit for musculoskeletal LBP, the investigators propose a clinical trial to evaluate whether combining muscle relaxants or opioids with NSAIDs is more effective than NSAID monotherapy for the treatment of non-traumatic, non-radicular low back pain. Specifically, the investigators will evaluate three distinct hypotheses:
- The combination of naproxen + cyclobenzaprine will provide greater relief of LBP than naproxen alone seven days after an ED visit, as measured by the Roland Morris low back pain functional disability scale
- The combination of naproxen + oxycodone/ acetaminophen will provide greater relief of LBP than naproxen alone seven days after an ED visit, as measured by the Roland Morris low back pain functional disability scale
- The combination of naproxen + oxycodone/ acetaminophen will provide greater relief of LBP than naproxen + cyclobenzaprine seven days after an ED visit, as measured by the Roland Morris low back pain functional disability scale
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Low Back Pain |
Drug: Naproxen Drug: Cyclobenzaprine Drug: Oxycodone/ acetaminophen |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized Three-armed Comparative Effectiveness Study of Various Medications for Musculoskeletal Low Back Pain: Defining the Added Benefit of Muscle Relaxants and Opioids. |
- Roland Morris low back pain functional disability scale [ Time Frame: 7 days after ER discharge ] [ Designated as safety issue: No ]This questionnaire has 24 distinct questions which assess the impact of the low back pain on a patient's functionality
| Estimated Enrollment: | 323 |
| Study Start Date: | April 2012 |
| Estimated Study Completion Date: | August 2014 |
| Estimated Primary Completion Date: | April 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Opioid
Naproxen + opioid
|
Drug: Naproxen
Naproxen 500mg twice/ day x 10 days
Drug: Oxycodone/ acetaminophen
Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
|
|
Active Comparator: Skeletal muscle relaxant
Naproxen + skeletal muscle relaxant
|
Drug: Naproxen
Naproxen 500mg twice/ day x 10 days
Drug: Cyclobenzaprine
Cyclobenzaprine 5-10mg three times/ day x 10 days
|
|
Active Comparator: Naproxen alone
Naproxen + placebo
|
Drug: Naproxen
Naproxen 500mg twice/ day x 10 days
|
Eligibility| Ages Eligible for Study: | 21 Years to 64 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Non-radicular, non-traumatic low back pain of no more than 2 weeks duration
Exclusion Criteria:
- Back pain longer than 2 weeks
- Prior to the acute attack of low back pain, back pain once per month or more frequently
- Prior to the acute attack of low back pain, daily or near daily use of pain medication
Contacts and Locations| United States, New York | |
| Montefiore Medical Center | Recruiting |
| Bronx, New York, United States, 10467 | |
| Contact: Benjamin W Friedman, MD, MS 718-920-6626 befriedm@montefiore.org | |
More Information
No publications provided
| Responsible Party: | Benjamin Friedman, Associate professor, Montefiore Medical Center |
| ClinicalTrials.gov Identifier: | NCT01587274 History of Changes |
| Other Study ID Numbers: | Low Back Pain RCT |
| Study First Received: | April 26, 2012 |
| Last Updated: | October 27, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Montefiore Medical Center:
|
low back pain |
Additional relevant MeSH terms:
|
Back Pain Low Back Pain Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Acetaminophen Naproxen Amitriptyline Acetaminophen, hydrocodone drug combination Oxycodone Cyclobenzaprine Neuromuscular Agents Analgesics, Opioid Antipyretics |
Physiological Effects of Drugs Pharmacologic Actions Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents Antirheumatic Agents Gout Suppressants Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 19, 2013